Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump DEI Purge Hits ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

A produtora do Ozempic, Novo Nordisk, planeja fabricar mais medicamentos para o mercado dos Estados Unidos localmente; a ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Overnight on Wall Street is morning in Europe.Monitor your investments 24 hours a day, around the clock from around the globe. Hosted by Caroline Hepker and Roger Hearing.

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Rep. Paul Tonko (D-N.Y.) and more than 50 colleagues in Congress sent a letter to HHS Secretary Robert F. Kennedy Jr.

Ignore the noise in GLP-1 stocks. Find the best value instead.

President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ties to healthcare and ...